G Curigliano MD PhD
@curijoey
Followers
8K
Following
5K
Media
550
Statuses
5K
Giuseppe Curigliano, MD, PhD, Professor at University of Milan and Head of Phase I Division at IEO, ESMO Open EiC, Tweets are my own
Milan, Italy
Joined June 2015
🎉 Congratulazioni ad Antonio Marra per aver vinto il prestigioso grant Next Generation AIRC!.Un traguardo straordinario che lo consacra tra gli oncologi del futuro. Si cura meglio solo se si fa ricerca.Avanti così, Antonio! 💪🔬 @LaStatale @IEOufficiale #NextGenAIRC.
Antonio Marra, oncologo medico della Divisione Nuovi Farmaci per Terapie Innovative IEO diretta da @curijoey , è stato selezionato tra i vincitori del Next Gen Clinician Scientist Grant, il prestigioso bando promosso da Fondazione AIRC per la ricerca sul cancro.
5
8
58
We were treated with zero respect or empathy, as if our time and well-being meant nothing. We expected at least a minimum level of care from a major airline, but United failed on every front. We will definitely not be flying with them again.
0
0
0
0
5
0
RT @Icro_Meattini: EMBER-3 PROMs results reinforce the benefit of Imlunestrant as monotherapy or in combination with abemaciclib as an all-….
0
7
0
RT @PTarantinoMD: Receiving the Yvonne “Top Voice” Award tonight was a honor. Receiving it from the hands of my first and lifelong mentor @….
0
12
0
RT @ProfSiowMingLee: 🙏 Honored to speak at the #BIGNCTN in Chicago with DavidBraun & @HaanenJohn. Grateful to share lung cancer vaccine ins….
0
3
0
Final OS of CheckMate 9LA.
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic NSCLC: final, 6-year outcomes from CheckMate 9LA in @ESMO_Open. Durable OS benefit as compared to platinum-based CT, no new safety signals.
0
9
26
Very important paper!.
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer in @ESMO_Open. 101 patients with solid tumors, ORR 77%, mDOR and mPFS 59 and 61 months, respectively. 88% of patients with TRAES, 26% of G3 or higher
0
10
29
RT @ESMO_Open: Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer in @ESMO_Open. 101 patients….
0
9
0
RT @VivekSubbiah: 🚨🥁Exciting Nature Medicine Publication Announcement .👉Hot off the press on this #ClinicalTrialsDay ! .Thrilled to share o….
0
71
0
RT @ErikaHamilton9: @curijoey masterfully discusses various response "thresholds" across tumor types with TDXd. Why. If same target? How….
0
6
0
RT @PabloMando: Take home messages of a comprehensive overview on response and toxicity prediction biomarkers in ADC @curijoey .✅Few curren….
0
5
0
RT @PTarantinoMD: The #CuriglianoLab and alumni at #ESMOBreast25! . From a group of Italian fellows to an international network of oncologi….
0
4
0
RT @PTarantinoMD: 🇮🇹 🇪🇸 🇺🇸 axis. United by friendship, passion and commitment to defeat breast cancer. @curijoey @JavierCortesMD #ESMOBrea….
0
7
0
RT @tscquizzato: “Si cura meglio solo se si fa ricerca.” Da leggere tutto d’un fiato, ispirazione per chiunque voglia fare ricerca e medici….
0
3
0
RT @bin_abeid: It was a great honour to be invited to the @AACR President's Dinner by the AACR president Dr. Patricia LoRusso at the ongoin….
0
3
0
RT @DrChoueiri: Some moments from #AACR25 meeting with @billdahutmd @curijoey @VanAllenLab @ZiadBakouny @CharlesSwanton and co-chairs @mvh_….
0
11
0
La medicina no es sólo ciencia, sino también un acto profundo de humanidad. El médico no es solo un técnico: es un servidor de la vida, llamado a sanar con conocimiento, pero también con compasión y ternura. Estados llamados a unir ciencia y conciencia, técnica y corazón.
1
6
39